AGC1-malate aspartate shuttle activity is critical for dopamine handling in the nigrostriatal pathway

Journal of Neurochemistry

Volumn 124, Issue 3, 2013, Pages 347-362

  Llorente Folch, Irene ^a   Sahún, Ignasi ^b   Contreras, Laura ^a   Casarejos, María José ^c   Grau, Josep María ^d   Saheki, Takeyori ^e   Mena, María Angeles ^c   Satrústegui, Jorgina ^a   Dierssen, Mara ^b   Pardo, Beatriz ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b CENTRE FOR GENOMIC REGULATION CRG   (Spain)

^c HOSPITAL RAMÓN Y CAJAL   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e KUMAMOTO UNIVERSITY   (Japan)

Author keywords

AGC 1 deficiency; dopamine; global cerebral hypomyelination; malate aspartate shuttle; OmniBank ; VMAT2

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 4 AMINOBUTYRIC ACID; ALANINE; AMINE OXIDASE (FLAVIN CONTAINING); AMINO ACID; AMPHETAMINE; ASPARTATE GLUTAMATE CARRIER 1; ASPARTIC ACID; CARRIER PROTEIN; DOPAMINE; GENOMIC DNA; GLUTAMIC ACID; GLUTAMINE; GLUTATHIONE; GLUTATHIONE DISULFIDE; MALIC ACID; MONOAMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; SERINE; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VESICULAR MONOAMINE TRANSPORTER 2;

ADULT ANIMAL; AMINO ACID BRAIN LEVEL; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; CYTOSOL; DOPAMINE BRAIN LEVEL; DOPAMINE METABOLISM; ENZYME ACTIVITY; FEMALE; HEMIZYGOTE; HYPERACTIVITY; KNOCKOUT MOUSE; MALE; MITOCHONDRION; MOTOR DYSFUNCTION; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; NUCLEOTIDE METABOLISM; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; PROTEIN EXPRESSION; TRANSPORT KINETICS;

AMINO ACID TRANSPORT SYSTEMS, ACIDIC; ANIMALS; ANTIPORTERS; ASPARTIC ACID; CORPUS STRIATUM; DOPAMINE; EMOTIONS; EXPLORATORY BEHAVIOR; FEMALE; HEREDITARY CENTRAL NERVOUS SYSTEM DEMYELINATING DISEASES; MALATES; MALE; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MITOCHONDRIAL DISEASES; MITOCHONDRIAL MEMBRANE TRANSPORT PROTEINS; MOTOR SKILLS DISORDERS; NEURAL PATHWAYS; OXIDATIVE STRESS; PREGNANCY; PSYCHOMOTOR DISORDERS; SUBSTANTIA NIGRA;

MUS;

EID: 84872081434     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12096     Document Type: Article

References (72)

1. 2-Implications for their role in disease, especially cancer. J. Bioenerg. Biomembr. 43, 541-564.
2. Altar C. A., Marien M. R., and, Marshall J. F., (1987) Time course of adaptations in dopamine biosynthesis, metabolism, and release following nigrostriatal lesions: implications for behavioral recovery from brain injury. J. Neurochem. 48, 390-399.
3. Andres A., Satrústegui J., and, Machado A., (1980) Development of NADPH producing pathways in rat heart. Biochem. J. 186, 799-803.
4. Berkich D. A., Ola M. S., Cole J., Sweatt A. J., Hutson S. M., and, LaNoue K. F., (2007) Mitochondrial transport proteins of the brain. J. Neurosci. Res. 85, 3367-3377.
5. Bernardi M. M., De Souza H., and, Palermo Neto J., (1981) Effects of single and long-term haloperidol administration on open field behavior of rats. Psychopharmacology 73, 171-175.
6. Brown E. E., Damsma G., Cumming P., and, Fibiger H. C., (1991) Intersticial 3-methoxytyramine reflects striatal dopamine release: an in vivo microdialysis study. J. Neurochem. 57, 701-707.
7. Cahoy J. D., Emery B., Kaushal A., et al,. (2008) A transcriptome database for astrocytes, neurons, and oligodendrocytes: a new resource for understanding brain development and function. J. Neurosci. 28, 264-278.
8. Canals S., Casarejos M. J., Rodriguez-Martin E., de Bernardo S., and, Mena M. A., (2001) Neurotrophic and neurotoxic effects of nitric oxide on fetal midbrain cultures. J. Neurochem. 76, 56-68.
9. Carlsson A., and, Lindqvist M., (1973) Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J. Pharm. Pharmacol. 25, 437-440.
10. Carola V., DÓlimpio F., Brunamonti E., Mangia F., and, Renzi P., (2002) Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behavior in inbred mice. Behav. Brain Res. 144, 49-57.
11. Caudle W. M., Richardson J. R., Shepherd K. R., Taylor T. N., Guillot T. S., McCormack A. L., Colebrooke R. E., Di Monte D. A., Emson P. C., and, Miller G. W., (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 8138-8148.
12. Chen M. K., Kuwabara H., Zhou Y., et al,. (2008a) VMAT2 and dopamine neuron loss in a primate model of Parkinson′s disease. J. Neurochem. 105, 78-90.
13. Chen L., Ding Y., Cagniard B., Van Laar A. D., Mortimer A., Chi W., Hastings T. G., and, kang U.J., and Zhuang X., (2008b) Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J. Neurosci. 28, 425-433.
14. Colebrooke R. E., Humby T., Lynch P. J., McGowan D. P., Xia J., and, Emson P. C., (2006) Age-related decline in striatal dopamine content and motor performance occurs in the absence of nigral cell loss in a genetic mouse model of Parkinson′s disease. Eur. J. Neurosci. 24, 2622-2630.
15. Contreras L., Urbieta A., Kobayashi K., Saheki T., and, Satrústegui J., (2010) Low levels of citrin (SLC25A13) expression in adult mouse brain restricted to neuronal clusters. J. Neurosci. Res. 88, 1009-1016.
16. Dawson T. M., Ko H. S., and, Dawson V. L., (2010) Genetic animal models of Parkinson′s disease. Neuron 66, 646-661.
17. Del Arco A., and, Satrústegui J., (1998) Molecular cloning of aralar, a new member of the mitochodrial carrier superfamily that binds calcium and is present in human muscle and brain. J. Biol. Chem. 273, 23327-23334.
18. Drechsel D. A., and, Patel M., (2008) Role of reactive oxygen species in the neurotoxicity of environmental agents implicated in Parlkinson′s disease. Free Radic. Biol. Med. 44, 1873-1886.
19. Fernandez S. P., and, Gaspar P., (2011) Investigating anxiety and depressive-like phenotypes in genetic mouse models of serotonin depletion. Neuropharmacology 62, 144-154.
20. Fienberg A. A., Hiroi N., Mermelstein P. G., et al,. (1998) DARPP-32: Regulator of the efficacy of dopaminergic neurotransmission. Science 281, 838-842.
21. Freeman H., Shimomura K., Horner E., Cox R. D., and, Ashcroft F. M., (2006) Nicotinamide nucleotide transhydrogenase: a key role in insulin secretion. Cell Metab. 3, 35-45.
22. Gõmez-Galán M., Makarova J., Llorente-Folch I., Saheki T., Pardo B., Satrústegui J., and, Herreras O., (2011) Altered postnatal development of cortico-hippocampal neuronal electric activity in mice deficient for the mitochondrial aspartate-glutamate transporter. J. Cereb. Blood Flow Metab. 32, 306-317.
23. Graham D. G., (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol. Pharmacol. 14, 633-643.
24. Griffith O.W., (1980) Determination of glutathione and glutathione disulfide using glutathione reductase and 2-vinylpyridine. Anal. Biochem. 106, 207-212.
25. Guo J. T., Chen A. N. Q., Kong Q. I., Zhu H., Ma C. M., and, Qin C., (2008) Inhibition of vesicular monoamine transporter-2 activity in -synuclein stably transfected SH-SY5Y cells. Cell. Mol. Neurobiol. 28, 35-47.
26. Han D., Antunes F., Canali R., Rettori D., and, Cadenas E., (2003) Voltage-dependent anion channels control the release of the superoxide anion from mitochondria to cytosol. J. Biol. Chem. 278, 5557-5563.
27. Hauber W., (1998) Involvement of basal ganglia transmitter system in movement initiation. Prog. Neurobiol. 56, 507-540.
28. Hefti F., Melamed E., and, Wurtman R. J., (1980) Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res. 195, 123-137.
29. Hirsch E., Graybiel A. M., and, Agid Y. A., (1988) Melanized dopaminergic neurons are diferentially susceptible to degeneration in Parkinson′s disease. Nature 334, 345-348.
30. Hornykiewicz O., and, Kish S. J., (1987) Biochemical pathophysiology of Parkinson′s disease. Adv. Neurol. 45, 19-34.
31. Husain R., Malaviya M., Seth P. K., and, Husain R., (1994) Effect of deltamethrin on regional brain polyamines and behaviour in young rats. Pharmacol. Toxicol. 74, 211-215.
32. Itier J.-M., Ibañez P., Mena M. A., et al,. (2003) Parkin gene inactivation alters behaviour and dopamine neurotransmission in the mouse. Hum. Mol. Genet. 12, 2277-2291.
33. Jalil M. A., Begum L., Contreras L., et al,. (2005) Reduced N- acetylaspartate levels in mice lacking Aralar, a brain- and muscle-type mitochondrial aspartate-glutamate carrier" J. Biol. Chem. 280, 31333-31339.
34. Lauder J. M., Han V. K., Henserson P., Verdoon T., and, Towle A. C., (1986) Prenatal ontogeny of the GABAergic system in the rat brain: an immunocytochemical study. Neuroscience 19, 465-493.
35. Liang C. L., Wang T. T., Luby-Phelps K., and, German D. C., (2007) Mitochondria mass is low in mouse substantia nigra dopamine neurons: implications for Parkinson′s disease. Exp. Neurol. 203, 370-380.
36. Liu M., Liu H., and, Dudley S. C. Jr, (2010) Reactive oxygen species originating from mitocondria regulate the cardiac sodium cannel. Circ. Res. 107, 967-974.
37. Lotharius J., and, Brundin P., (2002) Pathogenesis of Parkinson′s disease: dopamine, vesicles and alpha-synuclein. Nat. Rev. Neurosci. 3, 932-942.
38. Maker H. S., Weiss C., Silides D. J., and, Cohen G., (1981) Couple of dopamine oxidation monoamine oxidation via the generation of hydrogen peroxide in rat brain homogenates. J. Neurochem. 36, 589-593.
39. Martínez de Lagrán M., Altafaj X., Gallego X., Martí E., Estivill X., Sahún I., Fillat C., and, Dierssen M., (2004) Motor phenotypic alterations in TgDyrK1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction. Neurobiol. Disease 15, 132-142.
40. Meimaridou E., Kowalczyk J., Guasti L., et al,. (2012) Mutations in NNT encoding nicotinamide nucleotide transhydrogenase cause familial glucocorticoid deficiency. Nat. Genet. 44, 740-742.
41. Mena M. A., Pardo B., Paino C. L., and, De Yébenes J. G., (1993) Levodopa toxicity in foetal rat midbrain neurones in culture: modulation by ascorbic acid. NeuroReport 4, 438-440.
42. Mena M. A., Garcia de Yébenes M. J., Tabernero C., Casarejos M. J., Pardo B., and, Garcia de Yébenes J., (1995) Effects of calcium antagonists on the dopamine system. Clin. Neuropharmacol. 18, 410-426.
43. Mena M. A., Khan U., Togasaki D. M., Sulzer D., Epstein C. J., and, Przedborski S., (1997) Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J. Neurochem. 69, 21-33.
44. Mena M. A., de Bernardo S., Casarejos M. J., Canals S., and, Rodríguez-Martin E., (2002) The role of astroglia on the survival of dopamine neurons. Mol. Neurobiol. 25, 245-263.
45. Menéndez J., Rodríguez-Navarro J. A., Solano R. M., Casarejos M. J., Rodal I., Guerrero R., Sánchez M. P., Avila J., Mena M. A., and, de Yébenes J. G., (2006) Supression of parkin enhances nigrostriatal and motor neuron lesion in mice over-expressing human-mutated tau protein. Hum. Mol. Genet. 15, 2045-2058.
46. Mooslehner K. A., Chan P. M., Xu W., Liu L., Smadja C., Humby T., Allen N. D., Wilkinson L. S., and, Emson P. C., (2001) Mice with very low expression of the vesicular monoamine transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol. Cell. Biol. 21, 5321-5331.
47. Mosharov E. V., Staal R. G. W., Bové J., et al,. (2006) -synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 26, 9304-9311.
48. Murphy M. P., (2012) Mitochondrial thiols in antioxidant protection and redox signalling: distinct roles for glutathionylation and other thiol modifications. Antioxid. Redox Signal. 16, 476-495.
49. Nguyen N. H., Brathe A., and, Hassel B., (2003) Neuronal uptake and metabolism of glycerol and the neuronal expression of mitochondrial glycerol-3-phosphate dehydrogenase. J. Neurochem. 85, 831-842.
50. Palmiter R. D., (2008) Dopamine signaling in the dorsal striatum is essential for motivated behaviors. Lessons for dopamine-deficient mice. Ann. N. Y. Acad. Sci. 1129, 35-46.
51. Pardo B., Mena M. A., Casarejos M. J., Paino C. L., and, de Yébenes J. G., (1995) Toxic effects of L-DOPA on mesencephalic cell cultures: protection with antioxidants. Brain Res. 682, 133-143.
52. Pardo B., Contreras L., Serrano A., Ramos M., Kobayashi K., Iijima M., Saheki T., and, Satrústegui J., (2006) Essential role of aralar in the transduction of small calcium signals to neuronal mitochondria. J. Biol. Chem. 281, 1039-1047.
53. Pardo B., Rodrigues T. B., Contreras L., Garzõn M., Llorente-Folch I., Kobayashi K., Saheki T., Cerdán S., and, Satrústegui J., (2011) Brain glutamine synthesis requires neuronal-born aspartate as amino donor for glial glutamate formation. J. Cereb. Blood Flow Metab. 31, 90-101.
54. Pickrell A. M., Fukui H., Wang X., Pinto M., and, Moraes C., (2011) The striatum is highly susceptible to mitochondrial oxidative phosphorylation dysfunctions. J. Neurosci. 31, 9895-9904.
55. + -regulated mitochondrial aspartate-glutamate carrier aralar1 in brain and prominent expression in the spinal cord. Dev. Brain Res. 143, 33-46.
56. Ramos M., Pardo B., Llorente-Folch I., del Arco A., and, Satrústegui J., (2011) The deficiency in the mitochondrial transporter of aspartate/glutamate Aralar/AGC1 causes hypomyelination and neuronal defects unrelated to myelin deficits in mouse brain. J. Neurosci. Res. 89, 2008-2017.
57. Sakurai T., Ramoz N., Barreto M., et al,. (2010) Slc25a12 disruption alters myelination and neurofilaments: a model for a hypomyelination syndrome and childhood neurodevelopmental disorders. Biol. Psychiatry 67, 887-894.
58. Spina M. B., and, Cohen G., (1989) Dopamine turnover and glutathione oxidation: implications for Parkinson′s disease. Proc. Natl Acad. Sci. USA 88, 1398-1400.
59. Stein J. M., Bergman W., Fang Y., Davison L., Brensinger C., Robinson M. B., Hecht N. B., and, Abel T., (2006) Behavioral and neurochemical alterations in mice lacking tha RNA-binding protein translin. J. Neurosci. 26, 2184-2196.
60. Sterky F. H., Hoffman A. F., Milenkovic D., Bao B., Paganelli A., Edgar D., Wibom R., Lupica C. R., Olson L., and, Larsson N. G., (2012) Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. Hum. Mol. Genet. 21, 1078-1089.
61. Surmeier D. J., Guzman J. N., Sanchez-Padilla J., and, Schumacker P. T., (2011) The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson′s disease. Neuroscience 198, 221-231.
62. Taylor T. N., Caudle W. M., and, Miller G. W., (2011) VMAT2-deficient mice display nigral and extranigral pathology and motor and nonmotor symptoms of Parkinson′s disease. Parkinsons Dis. 2011, 124165.
63. Tietze F., (1969) Enzymatic method for quantitative determination of nanogram amounts of total and oxidized glutathione: application to mammalian blood and other tissues. Anal. Biochem. 27, 502-522.
64. Watabe M., and, Nakaki T., (2008) Mitochondrial complex I inhibitor rotenone inhibits and redistributes vesicular monoamine transporter 2 via nitration in human dopaminergic SH-SY5Y cells. Mol. Pharmacol. 74, 933-940.
65. White C. W., Mimmack R. F., and, Repine J. E., (1986) Accumulation of lung tissue oxidized glutathione (GSSG) as a marker of oxidant induced lung injury. Chest (Suppl.) 89, 111-113.
66. Wibom R., Lasorsa F. M., Töhönen V., et al,. (2009) AGC1 deficiency associated with global cerebral hypomyelination. N. Engl. J. Med. 361, 489-495.
67. Wood P. L., and, Altar C. A., (1988) Dopamine release in vivo from nigrostriatal, mesolimbic and mesocortical neurons: utility of 3-methoxytyramine measurements. Pharmacol. Rev. 40, 163-187.
68. Xu Y., Ola M. S., Berkich D. A., et al,. (2007) Energy sources for glutamate neurotransmission in the retina: absence of the aspartate/glutamate carrier produces reliance on glycolysis in glia. J. Neurochem. 101, 120-131.
69. Yin F., Sancheti H., and, Cadenas E., (2012) Silencing of nicotinamide nucleotide transhydrogenase impairs cellular redox homeostasis and energy metabolism in PC12 cells. Biochim. Biophys. Acta 1817, 401-409.
70. Zeevalk G. D., Manzino L., Hoppe J., and, Sonsalla P., (1997) In vivo vulnerability of dopamine neurons to inhibition of energy metabolism. Eur. J. Pharmacol. 320, 111-119.
71. 2 release at mitochondrial complex I. J. Biol. Chem. 280, 15587-15594.
72. Zweifel L. S., Fadok J. P., Argilli E., et al,. (2011) Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety. Nat. Neurosci. 14, 620-626.